BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31378480)

  • 1. Impact of residual nodal involvement after complete tumor response in patients undergoing neoadjuvant (chemo)radiotherapy for rectal cancer.
    Erkan A; Mendez A; Trepanier M; Kelly J; Nassif G; Albert MR; Lee L; Monson JRT
    Surgery; 2019 Oct; 166(4):648-654. PubMed ID: 31378480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodal Disease in Rectal Cancer Patients With Complete Tumor Response After Neoadjuvant Chemoradiation: Danger Below Calm Waters.
    Baucom RB; Maguire LH; Kavalukas SL; Geiger TM; Ford MM; Muldoon RL; Hopkins MB; Hawkins AT
    Dis Colon Rectum; 2017 Dec; 60(12):1260-1266. PubMed ID: 29112561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ypT0N+ status in oesophageal cancer patients: Location of residual metastatic lymph nodes with regard to the neoadjuvant radiation field.
    Schurink B; Seesing MFJ; Goense L; Mook S; Brosens LAA; Mohammad NH; Ruurda JP; Roeling TAP; Bleys RLAW; van Hillegersberg R
    Eur J Surg Oncol; 2019 Mar; 45(3):454-459. PubMed ID: 30503227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer.
    Sada YH; Tran Cao HS; Chang GJ; Artinyan A; Musher BL; Smaglo BG; Massarweh NN
    J Surg Res; 2018 Jun; 226():15-23. PubMed ID: 29661280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of neoadjuvant therapy on the size, number, and distribution of mesorectal lymph nodes.
    Yegen G; Keskin M; Büyük M; Kunduz E; Balık E; Sağlam EK; Kapran Y; Asoğlu O; Güllüoğlu M
    Ann Diagn Pathol; 2016 Feb; 20():29-35. PubMed ID: 26706785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Delaying Surgical Resection After Neoadjuvant Chemoradiation Impact Clinical Outcomes in Locally Advanced Rectal Adenocarcinoma?: A Single-Institution Experience.
    Nguyen P; Wuthrick E; Chablani P; Robinson A; Simmons L; Wu C; Arnold M; Harzman AE; Husain S; Schmidt C; Abdel-Misih S; Bekaii-Saab T; Chakravarti A; Williams TM
    Am J Clin Oncol; 2018 Feb; 41(2):140-146. PubMed ID: 26535992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
    Akiyoshi T; Toda S; Tominaga T; Oba K; Tomizawa K; Hanaoka Y; Nagasaki T; Konishi T; Matoba S; Fukunaga Y; Ueno M; Kuroyanagi H
    BJS Open; 2019 Dec; 3(6):822-829. PubMed ID: 31832589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Tominaga T; Akiyoshi T; Yamamoto N; Oba K; Nagasaki T; Yamaguchi T; Konishi T; Fukunaga Y; Ueno M
    Surgery; 2019 Dec; 166(6):1061-1067. PubMed ID: 31345564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Different Nodal Staging in Patients With Locally Advanced Mid-low Rectal Cancer After Long-term Neoadjuvant Chemoradiation Therapy.
    Petrucciani N; Carra MC; Martínez-Pérez A; Vitali GC; Landi F; Genova P; Memeo R; Brunetti F; Espin E; Ris F; De'angelis N;
    Anticancer Res; 2019 Apr; 39(4):2113-2120. PubMed ID: 30952757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lateral Nodal Features on Restaging Magnetic Resonance Imaging Associated With Lateral Local Recurrence in Low Rectal Cancer After Neoadjuvant Chemoradiotherapy or Radiotherapy.
    Ogura A; Konishi T; Beets GL; Cunningham C; Garcia-Aguilar J; Iversen H; Toda S; Lee IK; Lee HX; Uehara K; Lee P; Putter H; van de Velde CJH; Rutten HJT; Tuynman JB; Kusters M;
    JAMA Surg; 2019 Sep; 154(9):e192172. PubMed ID: 31268504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poorer Oncologic Outcome of Good Responders to PCRT With Remnant Lymph Nodes Defies the Oncologic Paradox in Patients With Rectal Cancer.
    Cho E; Park IJ; Hong SM; Lee JL; Kim CW; Yoon YS; Lim SB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2019 Jun; 18(2):e171-e178. PubMed ID: 31027968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status.
    Read TE; Andujar JE; Caushaj PF; Johnston DR; Dietz DW; Myerson RJ; Fleshman JW; Birnbaum EH; Mutch MG; Kodner IJ
    Dis Colon Rectum; 2004 Jun; 47(6):825-31. PubMed ID: 15108025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of lymph node retrieval in locoregional rectal cancer treated with chemoradiotherapy: a California Cancer Registry Study.
    Gill A; Brunson A; Lara P; Khatri V; Semrad TJ
    Eur J Surg Oncol; 2015 May; 41(5):647-52. PubMed ID: 25800934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the radiation-induced regression of positive nodes on survival in patients with rectal cancer treated with chemoradiotherapy.
    Beppu N; Kakuno A; Doi H; Kamikonya N; Matsubara N; Tomita N; Yanagi H; Yamanaka N
    Surgery; 2017 Feb; 161(2):422-432. PubMed ID: 27726913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
    Tan BR; Thomas F; Myerson RJ; Zehnbauer B; Trinkaus K; Malyapa RS; Mutch MG; Abbey EE; Alyasiry A; Fleshman JW; McLeod HL
    J Clin Oncol; 2011 Mar; 29(7):875-83. PubMed ID: 21205745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
    Sprenger T; Rothe H; Becker H; Beissbarth T; Homayounfar K; Gauss K; Kitz J; Wolff H; Scheel AH; Ghadimi M; Rödel C; Conradi LC; Liersch T
    Am J Surg Pathol; 2013 Aug; 37(8):1283-9. PubMed ID: 23851331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
    J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph nodes after preoperative chemoradiotherapy for rectal carcinoma: number, status, and impact on survival.
    Rullier A; Laurent C; Capdepont M; Vendrely V; Belleannée G; Bioulac-Sage P; Rullier E
    Am J Surg Pathol; 2008 Jan; 32(1):45-50. PubMed ID: 18162769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?
    Hughes R; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Livingstone JI; McDonald PJ; Meyrick Thomas J; Mitchell IC; Northover JM; Phillips R; Wallace M; Windsor A; Novell JR
    Int J Colorectal Dis; 2006 Jan; 21(1):11-7. PubMed ID: 15864605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.